Search for:
Category

Europe

Category

The Rating (Coronavirus) and Directors Disqualification (Dissolved Companies) Act (“Act”) received royal assent on 15 December 2021. The Act extends the scope of powers available to the Insolvency Service to address the issue of directors dissolving companies to avoid paying their liabilities.

Today, more than 28 million people in the EU work through digital platforms in a wide variety of sectors. With the aim of improving the working conditions of these platform workers, the Commission published a proposal for a Directive on 9 December 2021. According to the Commission, the proposed Directive should ensure greater protection of platform workers. If the Directive is adopted, European member states will have two years to adapt their national legislation accordingly.

Health Technology Assessment is a scientific evidence-based process that allows competent authorities to determine the relative effectiveness of new or existing health technologies. This multidisciplinary process evaluates the medical, social, economic and ethical issues related to the use of a health technology. Health technologies encompass medicines, medical devices, in vitro diagnostic medical devices and medical procedures, as well as measures for disease prevention, diagnosis or treatment.

On 26 November 2021, the FCA published Policy Statement 21/16 “Issuing statutory notices — a new approach to decision-makers” (“PS21/16”). In PS21/16, the FCA sets out the final changes to the Decisions Procedure and Penalties Manual and the Enforcement Guide as proposed in the Consultation Paper (CP21/25) published in July 2021. This transfers decision-making from the Regulatory Decisions Committee to the FCA in certain authorisation, intervention and straightforward cancellation cases and in respect of decisions on whether to commence civil and criminal proceedings from 26 November 2021.

Considering the cross-border component inherent to most Luxembourg transactions, dealmakers must carefully assess the risks of a merger control review even if the national merger thresholds are not met. To shed more certainty on the applicable procedure and timeline, the local M&A market may opt to insert detailed contractual remedies in the M&A documentation.